In this seconday analysis of a randomized clinical trial, serum samples from 60 participants in the Exenatide-PD trial were used to isolate neuronal-derived exosomes to evaluate levels of the brain insulin-signaling proteins and downstream effectors protein kinase B (Akt) and mechanistic target of rapamycin. After 48 and 60 weeks of subcutaneous drug administration, patients with Parkinson disease treated with exenatide had greater activation of brain insulin signaling proteins and downstream effectors compared with baseline and patients in the placebo group.
A Secondary Analysis of the Exenatide-PD ... - Cure Parkinson's
A Secondary Analysis of the Exenatide-PD Trial
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
I've read articles about Exenetide which are very encouraging
Not what you're looking for?
You may also like...
Exenatide : any non diabetic users? Update from those using for diabetes with PD?
was just prescribed Exenatide by my neurologist. He has faith in the Exenatide trial and has...
Neuromodulation for PD “Glove ++” : Trials | Observations | Tips | # 3
While reviewing the TP ( Trial Participants ) I noticed the prevalence of PWPnPD ( People With...
IPX203 shows sustained safety, efficacy in RISE-PD extension trial
Parkinson’s disease patients who participated in the open-label extension of the RISE-PD Phase 3...
Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD
newly diagnosed, treatment-naive patients received 1,000 mg NR or placebo for 30 days. NR treatment...